

**FINANCIAL STATEMENTS (Un-Audited)**  
**For the period from 01.01.2015 to 30.06.2015**



**THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.**

House No. 41, Road No. 10/A, Dhanmondi ,

Dhaka-1209, Bangladesh.

**THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.**

House # 41, Road # 10/A, Dhanmondi, Dhaka-1209

Muhtaram Shareholder(s),  
Assalamu Alaikum Wa Rahmatullah,

As per rule 13 of Securities and Exchange Rules-1987 and Bangladesh Accounting Standard (BAS) -34, we are pleased to enclose herewith the un-audited Statement of Financial Position as at 30th June 2015, the Statement of Profit or Loss and other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the half-year ended 30th June, 2015 for your kind perusal.


**STATEMENT OF FINANCIAL POSITION (Un-Audited)**

As at 30th June, 2015

			Amount in Taka	
Notes	As at 30.06.2015	As at 31.12.2014		
<b>ASSETS:</b>				
<b>Non-Current Assets:</b>				
Property, Plant and Equipment	02	533,029,361	726,757,066	782,494,963
Investment in Marketable Securities (AFS)	03	193,727,705	193,727,705	266,587,581
<b>Current Assets :</b>				
Inventories	04	160,259,688	432,298,027	412,684,597
Accounts Receivable		5,008,172	5,008,172	4,783,652
Advances, Deposits & Prepayments	05	117,487,340	117,487,340	99,815,239
Cash & Cash Equivalents	06	149,542,827	149,542,827	158,038,368
<b>TOTAL ASSETS</b>		<b>1,159,055,093</b>	<b>1,159,055,093</b>	<b>1,195,179,560</b>
<b>SHAREHOLDERS' EQUITY AND LIABILITIES:</b>				
<b>Shareholders' Equity:</b>				
Share Capital		224,532,000	603,680,654	679,344,704
Net Gain on Marketable Securities (AFS)	03	140,643,852	140,643,852	206,217,741
Tax Holiday Reserve		4,392,110	4,392,110	4,392,110
Retained Earnings	07	234,112,692	234,112,692	254,894,853
Non-Current Liabilities	08	148,051,930	148,051,930	84,044,694
Deferred Tax Liability	09	23,672,090	23,672,090	30,841,557
<b>Current Liabilities:</b>				
Bank Finance & Other Credits	10	146,521,395	383,650,419	400,948,605
Accounts and Other Payable	11	237,129,024	237,129,024	200,747,648
<b>TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES</b>		<b>1,159,055,093</b>	<b>1,159,055,093</b>	<b>1,195,179,560</b>

Dated, Dhaka  
26-Jul-15

  
(Md. Jasim Uddin, FCA)  
Chief Financial Officer

  
(Prof. Dr. A.K.M. Sadrul Islam)  
Managing Director (Acting)

Amount in Taka

	Notes	For the half-year (January 01, 2015 to June 30, 2015)	For the half-year (January 01, 2014 to June 30, 2014) Restated	For the Quarter (April 01, 2015 to June 30, 2015)	For the Quarter (April 01, 2014 to June 30, 2014) Restated
Turnover and Other income		1,488,631,918	1,244,410,664	804,479,928	697,043,588
Cost of goods sold	12	(895,435,370)	(751,623,397)	(545,556,515)	(469,285,580)
<b>Gross Profit</b>		<b>593,196,548</b>	<b>492,787,267</b>	<b>258,923,413</b>	<b>227,758,008</b>
<b>Operating Expenses:</b>					
Administrative expenses	13	(37,930,231)	(35,896,364)	(19,523,708)	(20,280,984)
Selling & Distribution expenses	14	(479,742,870)	(401,901,504)	(198,929,729)	(175,768,544)
		<b>(517,673,101)</b>	<b>(437,797,868)</b>	<b>(218,453,437)</b>	<b>(196,049,528)</b>
<b>Operating Profit</b>		<b>75,523,447</b>	<b>54,989,399</b>	<b>40,469,976</b>	<b>31,708,480</b>
Workers' P.P. Fund & Welfare Fund		(3,596,355)	(2,618,543)	(1,927,142)	(1,509,928)
<b>Net Profit before tax</b>		<b>71,927,092</b>	<b>52,370,856</b>	<b>38,542,834</b>	<b>30,198,552</b>
Less: Income tax expenses					
Current tax		(17,981,773)	(14,401,985)	(9,635,709)	(8,304,602)
Deferred tax	09	116,520	(206,083)	410,937	489,260
		<b>(17,865,253)</b>	<b>(14,608,068)</b>	<b>(9,224,772)</b>	<b>(7,815,342)</b>
<b>Net Profit after tax</b>		<b>54,061,839</b>	<b>37,762,788</b>	<b>29,318,063</b>	<b>22,383,210</b>
<b>Other Comprehensive Income:</b>					
Change in fair value of Marketable Securities (AFS)	03	(72,859,876)	(64,987,803)	(35,407,716)	(64,158,560)
Deferred tax		7,285,987	6,498,780	3,540,772	6,415,856
Total other comprehensive income for the period, net of tax		<b>(65,573,889)</b>	<b>(58,489,023)</b>	<b>(31,866,944)</b>	<b>(57,742,704)</b>
<b>Total other comprehensive income for the period 30th June, 2015</b>		<b>(11,512,050)</b>	<b>(20,726,235)</b>	<b>(2,548,882)</b>	<b>(35,359,494)</b>
<b>Earnings per share (EPS)-basic (restated-2014)</b>		<b><u>2.41</u></b>	<b><u>1.68</u></b>	<b><u>1.31</u></b>	<b><u>1.00</u></b>
<b>Net Asset Value (NAV) per share</b>		<b><u>26.89</u></b>	<b><u>29.40</u></b>		
<b>Net Operating cash flow per share (NOCFPS)</b>		<b><u>2.24</u></b>	<b><u>3.85</u></b>		

Dated , Dhaka  
26-Jul-15

  
(Md. Jasim Uddin, FCA)  
Chief Financial Officer

  
(Prof. Dr. A.K. M. Sadrul Islam)  
Managing Director (Acting)

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.

STATEMENT OF CHANGES IN EQUITY (Un-Audited)

For the Half-year ended 30th June, 2015

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (Unrealized)	Retained Earnings	Total
Balance as at 1st January, 2014	194,400,000	4,392,110	279,141,244	195,656,433	673,589,787
Dividend for the year, 2013	19,440,000	-		(68,040,000)	(48,600,000)
Total Comprehensive Income/(Loss)-2014	-	-	(72,923,503)	127,278,420	54,354,917
Balance as at 1st January, 2015	213,840,000	4,392,110	206,217,741	254,894,853	679,344,704
Total Comprehensive Income/(Loss) for the period ended 30th June, 2015			(65,573,889)	54,061,839	(11,512,050)
Dividend for the year, 2014 (Cash-30%)				(64,152,000)	(64,152,000)
Dividend for the year, 2014 (Stock-05%)	10,692,000			(10,692,000)	-
Balance as at 30th June, 2015	224,532,000	4,392,110	140,643,852	234,112,692	603,680,654

STATEMENT OF CHANGES IN EQUITY (Un-Audited)

For the Half-year ended 30th June, 2014

Restated

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (Unrealized)	Retained Earnings	Total
Balance as at 1st January, 2013	162,000,000	4,392,110	296,770,285	165,179,622	628,342,017
Dividend for the year, 2012	32,400,000	-		(56,700,000)	(24,300,000)
Statement of profit or loss and other comprehensive Income, 2013			(17,629,041)	87,176,811	69,547,770
Balance as at 1st January, 2014	194,400,000	4,392,110	279,141,244	195,656,433	673,589,787
Dividend for the year, 2013 (Cash-25%)				(48,600,000)	(48,600,000)
Dividend for the year, 2013 (Stock-10%)	19,440,000			(19,440,000)	-
Statement of profit or loss and other Comprehensive Income for the period ended 30th June, 2014			(58,489,023)	37,762,788	(20,726,235)
Balance as at 30th June, 2014	213,840,000	4,392,110	220,652,221	165,379,221	604,263,552

Dated, Dhaka  
26-Jul-15

  
(Md. Jasim Uddin, FCA)  
Chief Financial Officer

  
(Prof. Dr. A.K. M. Sadrul Islam)  
Managing Director (Acting)

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.  
STATEMENT OF CASH FLOWS (Un-Audited)  
For the Half-year ended 30th June, 2015

	Amount in Taka	
	Half-year ended 30.06.2015	Half-year ended 30.06.2014
<b>Cash Flow From Operating Activities:</b>		
Collection from customers & others	1,474,243,393	1,236,975,032
Payment for cost & expenses	(1,406,841,702)	(1,132,575,887)
Other income	484,730	531,976
<b>Cash generated from operations</b>	<b>67,886,421</b>	<b>104,931,121</b>
Income tax paid	(14,567,292)	(21,286,479)
Financial charges	(3,077,321)	(1,254,667)
<b>Net cash provided by operating activities</b>	<b>50,241,808</b>	<b>82,389,975</b>
<b>Cash Flow From Investing Activities:</b>		
Purchase of fixed assets	(40,192,498)	(45,672,096)
Investment	-	(12,565,133)
Dividend income	13,216,789	6,114,996
Profit from bank deposits & investment	462,486	230,340
<b>Net cash used in investing activities</b>	<b>(26,513,223)</b>	<b>(51,891,893)</b>
<b>Cash Flow From Financing Activities:</b>		
Payment of dividend	(13,869,515)	(23,351,476)
Long term finance received/(paid) from bank (net)	53,407,636	4,231,528
Short term finance received/(paid) from bank (net)	(61,855,853)	(6,442,215)
Changes in other finance	(9,906,395)	(15,171,052)
<b>Net cash flow from financing activities</b>	<b>(32,224,127)</b>	<b>(40,733,215)</b>
Increase/(decrease) in cash and cash equivalents	(8,495,541)	(10,235,133)
Cash and cash equivalents at the opening	158,038,368	119,698,358
<b>Cash and cash equivalents at the closing</b>	<b><u>149,542,827</u></b>	<b><u>109,463,225</u></b>

Dated, Dhaka  
26-Jul-15

  
(Md. Jasim Uddin, FCA)  
Chief Financial Officer

  
(Prof. Dr. A.K. M. Sadrul Islam)  
Managing Director (Acting)

**The Ibn Sina Pharmaceutical Industry Ltd.**  
**Selected Notes to the Financial Statements (Un-Audited)**

For the Half-year ended 30th June, 2015

**Selected Explanatory Notes**

**Basis of Preparation of Financial Statements**

These financial Statements have been prepared in line with the accounting policies and methods of computations of the annual financial statements prepared and published for the year ended 31st December, 2014. These interim financial statements includes only selected explanatory notes as deemed appropriate for understanding of these un-audited financial statements.

**Reporting**

This half-yearly financial report has been prepared based on Bangladesh Accounting Standard (BAS)-34 "Interim Financial Reporting".

**Earnings Per Share (EPS)**

Earnings per share has been calculated based on number of shares outstanding for the period ended June 30, 2015 and profit for the same period. The number of shares outstanding for the period was 22.4532 million. Earnings per share for the corresponding period of 2014 has also been calculated based on 22.4532 million shares. No diluted earnings per share is required to be calculated as there was no scope for dilution during the period under review.

**Restatement of Financial Statement:**

Statement of profit or loss and other comprehensive income and statement of changes in equity for the half-year ended on 30th June 2014 has been restated for more compliance with accounting standard by recognising deferred tax on gain/(loss) of marketable securities (available for sales, AFS).

**Subsequent events**

No Material events occurred after the reporting date, non disclosure of which could affect the stakeholders to make proper valuation and decision.

Previous period figures have been re-arranged to conform to current period's presentation, where considered necessary.

**PROPERTY, PLANT AND EQUIPMENT:**

**Cost/Revaluation**

	Amount in Taka	
	As at 30.06.2015	As at 31.12.2014
Balance as at 1st January	834,827,102	668,062,064
Addition during the year	40,192,498	167,600,458
Disposal/Adjustment during the year	-	(835,420)
	875,019,600	834,827,102

**Accumulated Depreciation**

Balance as at 1st January	318,919,720	284,415,581
Charged during the year	23,070,519	35,164,359
Disposal/Adjustment during the year	-	(660,220)
	341,990,239	318,919,720

**Written Down Value (WDV)**

	533,029,361	515,907,382
--	-------------	-------------

**INVESTMENT IN MARKETABLE SECURITIES (FAIR VALUE):**

Name of Company Share/Bond	No. of Shares /Bond Held	Face Value Per Share /Bond	Cost of Holding	Average Cost	Quoted Rate Per Share/ Bond as on 30.06.15	Total Market value of shares/ Bond as on 30.06.15	Unrealized Gain/(Loss)
Islami Bank Bangladesh Ltd. (IBBL)- in shares	11,013,991	10	32,866,758	2.98	17.20	189,440,645	156,573,887
Islami Bank Bangladesh Ltd. (IBBL)-in Mudaraba Perpetual Bond (MPB)	4,590	1,000	4,590,000	1,000	934.00	4,287,060	(302,940)
<b>Total Taka</b>			<b>37,456,758</b>			<b>193,727,705</b>	<b>156,270,947</b>

**NET GAIN/(LOSS) ON MARKETABLE SECURITIES (AFS) :**

Unrealized Gain/(Loss) Position (Closing)

Deferred tax on gain on marketable securities (AFS)

Amount in Taka	
As at 30.06.2015	As at 31.12.2014

156,270,947	229,130,823
(15,627,095)	(22,913,082)
<b>140,643,852</b>	<b>206,217,741</b>

**CHANGE IN FAIR VALUE OF MARKETABLE SECURITIES (AFS) :**

Unrealized Gain/(Loss) Position (Closing)

Unrealized Gain/(Loss) Position (Opening)

156,270,947	229,130,823
229,130,823	310,156,936
<b>(72,859,876)</b>	<b>(81,026,113)</b>

**INVENTORIES:**

Raw materials

Packing materials

Work-in-process

Finished goods

Physicians' samples &amp; others

52,262,798	48,139,256
45,672,126	40,546,705
21,083,162	20,559,600
40,375,599	40,039,010
866,003	762,767
<b>160,259,688</b>	<b>150,047,338</b>

**ADVANCES, DEPOSITS & PRE-PAYMENTS :***This is recoverable in cash or for value to be received and consists of as follows :***a. Advances against-**

Salary

Expenses/Works

Sales centre rent

Motor cycles - to employees

Income Tax

Others

754,650	1,610,401
18,641,198	19,310,512
3,020,110	2,110,000
12,319,434	6,508,928
69,031,234	55,698,743
253,776	173,169
<b>104,020,402</b>	<b>85,411,753</b>

**b. Deposits -**

Security money

3,705,997

4,517,746

**c. Pre-payments -**

Value Added Tax (VAT)

Insurance premium

9,211,668	9,490,769
549,273	394,971
<b>9,760,941</b>	<b>9,885,740</b>

**Total Amount (a+b+c)****117,487,340****99,815,239****CASH & CASH EQUIVALENTS:**

Cash in hand &amp; Bank Balance

Imprest Cash

143,621,477	151,682,368
5,921,350	6,356,000
<b>149,542,827</b>	<b>158,038,368</b>

**RETAINED EARNINGS :**

Retained Earnings

Dividend Paid

Add : Surplus during the period/year

254,894,853	195,656,433
(74,844,000)	(68,040,000)
54,061,839	127,278,420
<b>234,112,692</b>	<b>254,894,853</b>

**NON-CURRENT LIABILITIES:**

Long Term Finance-Net off current maturity

Retirement Benefit Obligation

86,524,602	33,116,966
61,527,328	50,927,728
<b>148,051,930</b>	<b>84,044,694</b>

**DEFERRED TAX ASSET/LIABILITY :**

Deferred Tax Asset/Liability represents deferred tax recognized as asset/liability the movement of which is as below:

**a) Deferred tax liability on net temporary differences:**

Balance as at 1st January

Deferred tax expenses/(income)

7,928,475	5,243,267
116,520	2,685,208
<b>8,044,995</b>	<b>7,928,475</b>

**b) Deferred tax liability on change in AFS :**

Balance as at 1st January  
Addition/(Less) during the year

**Deferred tax liability at closing balance (a+b)**

Amount in Taka	
As at 30.06.2015	As at 31.12.2014
22,913,082	31,015,694
(7,285,987)	(8,102,612)
<b>15,627,095</b>	<b>22,913,082</b>
<b>23,672,090</b>	<b>30,841,557</b>

**BANK FINANCE & OTHER CREDITS :**

Short Term Finance  
Long Term Finance-Current maturity  
Deposits  
Other Finance

66,382,433	135,592,500
18,068,079	10,713,865
13,016,401	12,929,848
49,054,482	40,964,744
<b>146,521,395</b>	<b>200,200,957</b>

**ACCOUNTS AND OTHER PAYABLES:**

Payable for Suppliers  
Accrued Expenses  
Income Tax Liability

101,888,426	88,850,633
75,187,182	68,590,571
60,053,416	43,306,444
<b>237,129,024</b>	<b>200,747,648</b>

**COST OF GOODS SOLD :**

Materials  
Factory Overhead  
Depreciation

Amount in Taka	
For the half-year (January 01, 2015 to June 30, 2015)	For the half-year (January 01, 2014 to June 30, 2014)
766,342,450	654,121,698
110,675,584	84,561,974
18,417,336	12,939,725
<b>895,435,370</b>	<b>751,623,397</b>

**ADMINISTRATIVE EXPENSES :**

Salary, wages & Allowances  
Repairs & Maintenance  
Travelling & Conveyance  
AGM, Fees and Others  
Depreciation  
Other Expenses

20,747,965	19,736,177
2,566,950	2,421,222
1,131,243	902,750
1,685,565	1,283,208
1,554,840	1,478,075
10,243,668	10,074,932
<b>37,930,231</b>	<b>35,896,364</b>

**SELLING & DISTRIBUTION EXPENSES :**

Salary, wages & Allowances  
Travelling & Conveyance  
Market Survey & Research and Product development  
Field personnel expenses  
Sample, Literature & Promotional Expenses  
Delivery Expenses  
Depreciation  
Other Expenses

243,059,277	197,034,640
581,680	567,114
1,064,080	1,253,498
60,805,196	59,739,400
63,845,579	56,174,520
53,726,951	47,886,423
3,098,343	1,895,251
53,561,763	37,350,658
<b>479,742,870</b>	<b>401,901,504</b>

Dated, Dhaka  
26-Jul-15

  
(Md. Jasim Uddin, FCA)  
Chief Financial Officer

  
(Prof. Dr. A.K. M. Sadrul Islam)  
Managing Director (Acting)